Novo Nordisk has mitigation plans to minimize disruption from port strikes, CNBC reports

(Reuters) - Danish drugmaker Novo Nordisk (NYSE:NVO ) has mitigation plans in place to minimize or prevent any disruption to its production due to sea port strikes in the United States, CNBC reported on Tuesday citing a company spokesperson.

The maker of popular drugs, Wegovy and Ozempic, plans to ship its products to and from the U.S. via air freight, the report added.

Novo did not immediately respond to Reuters' request for comment.

The company imports some of its active pharmaceutical ingredient, or semaglutide, into the U.S. for its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy, according to the report.



The U.S. Department of Health and Human Services (HHS) said earlier on Tuesday its preliminary analysis showed a strike by U.S. East Coast and Gulf Coast dockworkers should have a limited impact on the availability of essential goods such as medicines and medical devices.

The dockworkers began their first large-scale stoppage in nearly 50 years, halting about half the country's ocean shipping after negotiations for a new labor contract broke down over wages.

Source: Investing.com